AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00326872 |
Recruitment Status :
Terminated
(Closed due to slow accrual prior to interim analysis.)
First Posted : May 17, 2006
Results First Posted : September 26, 2013
Last Update Posted : August 18, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neurofibromatosis Type 1 Plexiform Neurofibroma Spinal Cord Neurofibroma | Drug: Cediranib Maleate | Phase 2 |
PRIMARY OBJECTIVES:
I. Assess the efficacy of AZD2171, in terms of volume change in target tumors by 3-dimensional magnetic resonance imaging (3D MRI).
II. Describe and define the toxicities of AZD2171 in these patients.
SECONDARY OBJECTIVES:
I. Assess the value of 3D MRI data analysis in evaluating plexiform or paraspinal neurofibromas compared to conventional 2-dimensional MRI data analysis.
II. Assess the value of delayed contrast-enhanced MRI (DCE-MRI) in determining changes in vascularity of neurofibromas before and during treatment. III. Assess the quality of life of patients treated with AZD2171. IV. Evaluate the effect of AZD2171 on biological changes of human neurofibroma by comparing pre- and post-treatment specimens from patients involved in this trial or, alternatively, by evaluating the effect of AZD2171 on human tumor grafts in experimental animals.
V. Evaluate relevant pharmacodynamic markers (circulating endothelial cells [CECs] and vascular endothelial growth factor-2 [VEGF2] levels) and pharmacogenetics analyses (variation in kdr/flk-1 and other genes) in response to AZD2171.
OUTLINE: This is a multicenter study. Patients are stratified according to tumor location (peripheral vs paraspinal plexiform neurofibroma). Patients receive oral AZD2171 once daily on days 1-28.
Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to course 2, prior to course 4, and every 6 courses thereafter.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 26 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas |
Study Start Date : | May 2006 |
Actual Primary Completion Date : | August 21, 2011 |
Actual Study Completion Date : | May 31, 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (cediranib maleate)
Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to course 2, prior to course 4, and every 6 courses thereafter.
|
Drug: Cediranib Maleate
Other Names:
|
- Proportion of Patients With Tumor Response (Complete Response [CR] or Partial Response [PR]) [ Time Frame: Baseline to end of treatment, maximum of 26 cycles (28 days/cycle). ]
Complete Response (CR): Disappearance of all target lesions.
Partial Response (PR): At least a 30% decrease in the volume of target lesions taking as reference the baseline volume.
- Survival Time as Measured Using Kaplan-Meier Method [ Time Frame: From registration to death (due to any cause) max 51 months ]Survival time is defined as the time from registration to death due to any cause.
- Time to Disease Progression as Measured Using Kaplan-Meier Method [ Time Frame: From registration to documentation of disease progression up to 26 cycles (28 days/cycle). ]
Progression (PD): At least a 20% increase in the sum of volumes of target lesions taking as reference the smallest volume recorded since the treatment started or the appearance of one or more new lesions.
If a patient dies without documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death.
- Duration of Response as Assessed Using the Method of Kaplan-Meier [ Time Frame: From time of confirmed tumor objective response as CR or PR to the date of progression max 51 months ]Duration of response is defined for all evaluable patients who have achieved a confirmed tumor objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented. Duration of response will be estimated using the method of Kaplan-Meier.
- Time to Treatment Failure as Assessed Using the Method of Kaplan-Meier [ Time Frame: From the date of randomization to the date at which the patient is removed from treatment due to progression, toxicity, or refusal up to 51 months. ]
Time to treatment failure is defined to be the time from the date of randomization to the date at which the patient is removed from treatment due to progression, toxicity, or refusal. If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they are removed from treatment.
Time to treatment failure will be estimated using the method of Kaplan-Meier.
- Reduction in Self Reported Worst Pain Per Cycle. [ Time Frame: At baseline, prior to each subsequent course (q 28+/- 3 days), and at end of treatment up to 51 months ]Reduction in self reported worst pain per cycle as measured by the Worst Pain scale from the North Central Cancer Treatment Group Brief Pain Inventory (short form). The worst pain scale is from 0-10 (10 is worst pain possible). The per-cycle average reduction in worst pain will be analyzed using generalized linear models to account for repeated measures within patients.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Diagnosis* of neurofibromatosis type 1 (NF1) and extensive plexiform and/or paraspinal neurofibromasproducing pain (not controlled by use of over-the-counter medications), progressive neurologic deficit, or significant neurologic consequenceswith continuous tumor growth
-
Extensive paraspinal neurofibroma defined as a neurofibroma that involves multiple neural roots at ≥ 3 spinal levels with connection between the levels or extending laterally along the nerves
- Symptomatic neurofibromas at < 3 spinal levels, but surgical treatment is not possible, allowed
-
-
Meets ≥ 2 diagnostic criteria for NF1, including the following:
- Six or more café-au-lait spots (≥ 1.5 cm in postpubertal patients)
- Freckling in the axilla or groin
- Optic glioma
- Two or more Lisch nodules
- Distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia orthinning of long-bone cortex)
- First-degree relative with NF1
- Patients with documented mutation in neurofibromin gene with onlysymptomatic plexiform and/or paraspinal neurofibroma who do not fulfill the above clinical criteria are eligible
-
Measurable disease, defined as ≥ 1 lesion whose longest diameter can beaccurately measured as 8.0 cm^3 with 3-dimensional (3D) MRI
- Skin lesions are consideredmeasurable (e.g., plexiform neurofibromas), but MRI imaging still required for 3D measurement
- Patients with symptomatic neurofibroma, in whom surgery is not feasible, who refuse surgery or are not goodsurgical candidates due to high risk of damage to vital structures or spinal cordinjury are eligible
- No evidence of progressive optic glioma, malignant glioma, malignant peripheralnerve sheath tumor, or other cancer requiring treatment with chemotherapy orradiotherapy
- ECOG performance status 0-3
- WBC ≥ 3,000/mm^3
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 8.0 g/dL
- Bilirubin normal (patients with Gilbert's syndrome allowed despite elevated bilirubin)
- Alkaline phosphatase normal
- AST and ALT ≤ 2.5 times upper limit of normal
- Thyroid-stimulating hormone and free thyroxin normal
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- Ejection fraction ≥ 50% by echocardiogram
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
-
No other uncontrolled, serious medical condition that would preclude study participation, including any of the following:
- Cardiac arrhythmia
- Diabetes
- Serious infection
- Significant cardiac, pulmonary, hepatic, or other organ dysfunction
- No psychiatric illness or social situation that would preclude study compliance
- No history of allergic reactions attributed to compounds of similar chemical orbiologic composition to AZD2171
-
No New York Heart Association class III or IV disease
- Class II disease controlled with treatment and increased monitoring allowed
- No systolic blood pressure (BP) > 130 mm Hg and diastolic BP > 90 mm Hg
- No history of familial long QT syndrome
- Mean QTc ≤ 470 msec (with Bazett's correction) by EKG
- QTc prolongation ≤ 500 msec
- No other significant ECG abnormality within the past 14 days
- See Disease Characteristics
- More than 30 days since prior investigational agents
- More than 4 weeks since prior radiotherapy, chemotherapy, hormonal therapy directed at thetumor, immunotherapy, biologic therapy (e.g., interferon), or majorsurgery
- No concurrent medication that may markedly affect renal function (e.g., vancomycin, amphotericin, or pentamidine)
- No concurrent CYP interactive medications
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, carbamazepine, or phenobarbital)
- No concurrent use of drugs or biologics with proarrhythmic potential

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00326872
United States, Alabama | |
University of Alabama at Birmingham Cancer Center | |
Birmingham, Alabama, United States, 35233 | |
United States, District of Columbia | |
Howard University Hospital | |
Washington, D.C., District of Columbia, United States, 20060 | |
United States, Illinois | |
University of Chicago Comprehensive Cancer Center | |
Chicago, Illinois, United States, 60637 | |
United States, Massachusetts | |
Massachusetts General Hospital Cancer Center | |
Boston, Massachusetts, United States, 02114 | |
Dana-Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 | |
United States, Michigan | |
Wayne State University/Karmanos Cancer Institute | |
Detroit, Michigan, United States, 48201 | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
United States, Missouri | |
Washington University School of Medicine | |
Saint Louis, Missouri, United States, 63110 | |
United States, Ohio | |
Case Western Reserve University | |
Cleveland, Ohio, United States, 44106 |
Principal Investigator: | Dusica Babovic-Vuksanovic | Mayo Clinic |
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00326872 |
Obsolete Identifiers: | NCT01646970, NCT01664390 |
Other Study ID Numbers: |
NCI-2009-00128 NCI-2009-00128 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) MC047F CDR0000475761 MC047F ( Other Identifier: Mayo Clinic ) 7133 ( Other Identifier: CTEP ) N01CM17104 ( U.S. NIH Grant/Contract ) N01CM62205 ( U.S. NIH Grant/Contract ) P30CA015083 ( U.S. NIH Grant/Contract ) |
First Posted: | May 17, 2006 Key Record Dates |
Results First Posted: | September 26, 2013 |
Last Update Posted: | August 18, 2017 |
Last Verified: | July 2017 |
Neurofibromatoses Neurofibromatosis 1 Neurofibroma Neurofibroma, Plexiform Nerve Sheath Neoplasms Neoplasms, Nerve Tissue Neoplasms by Histologic Type Neoplasms Neoplastic Syndromes, Hereditary Neurocutaneous Syndromes Nervous System Diseases Heredodegenerative Disorders, Nervous System |
Neurodegenerative Diseases Genetic Diseases, Inborn Peripheral Nervous System Diseases Neuromuscular Diseases Peripheral Nervous System Neoplasms Nervous System Neoplasms Cediranib Maleic acid Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Protein Kinase Inhibitors |